Management of risk of breast carcinoma in postmenopausal women

Endocrine-Related Cancer

Volumn 11, Issue 1, 2004, Pages 69-83

  Biglia, N ^a   Defabiani, E ^a   Ponzone, R ^a   Mariani, L ^a   Marenco, D ^a   Sismondi, P ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ALCOHOL CONSUMPTION; BREAST CARCINOMA; BREAST DUCT; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; FAT INTAKE; FEMALE; FLUID RETENTION; GENE MUTATION; HEALTH BEHAVIOR; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERPLASIA; LEG CRAMP; LIFESTYLE; LOW DRUG DOSE; LUNG EMBOLISM; MASTECTOMY; MENARCHE; MENOPAUSE; OBESITY; ONCOGENE; POPULATION; POSTMENOPAUSE; RELATIVE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SENESCENCE; SIDE EFFECT;

ANTHROPOMETRY; BREAST NEOPLASMS; CARCINOMA; FEMALE; HORMONES; HUMANS; LIFE STYLE; POSTMENOPAUSE; RISK FACTORS;

EID: 1842576885     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110069     Document Type: Review

References (101)

1. Armstrong K, Eisen A & Weber B 2000 Assessing the risk of breast cancer. New England Journal of Medicine 342 564-571.
2. Baron JA, Newcomb PA, Longnecker MP, Mittendorf R, Storer BE, Clapp RW, Bogdan G & Yuen J 1996 Cigarette smoking and breast cancer. Cancer Epidemiology Biomarkers and Prevention 5 399-403.
3. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P & Harper KD 2002 Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-years results from MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Journal of the American Medical Association 287 847-857.
4. Bergkvist L, Adami HO, Persson I, Bergstrom R & Krusemo UB 1989 Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. American Journal of Epidemiology 130 221-228.
5. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM & Piana L 1995 Clinical and biological prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstetrics and Gynecology 85 11-17.
6. Borgen PI, Hill AD, Tran KN, Van Zee KJ, Massie MJ, Payne D & Biggs CG 1998 Patients regrets after bilateral prophylactic mastectomy. Annals of Surgical Oncology 7 603-606.
7. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL & Yaffe MJ 1995 Quantitative classification of mammographic densities and breast cancer risk: results from Canadian National Breast Cancer Screening Study. Journal of the National Cancer Institute 87 670-675.
8. Buist DS, LaCroix AZ, Barlow WE, White E & Weiss NS 2001 Bone mineral density and breast cancer risk in postmenopausal women. Journal of Clinical Epidemiology 54 417-422.
9. Bush TL, Whiteman M & Flaws JA 2001 Hormone replacement therapy and breast cancer: a qualitative review. Obstetrics and Gynecology 98 498-508.
10. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R & Haile R 1995 Mammographic features and breast cancer risk: effects with time, age, and menopause status. Journal of the National Cancer Institute 87 1622-1629.
11. Byrne C, Rockett H. & Holmes MD 2002 Dietary fat, fat subtypes, and breast cancer risk: lack of an association among postmenopausal women with no history of benign breast disease. Cancer Epidemiology Biomarkers and Prevention 11 261-265.
12. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS & Cummings SR 1996 Bone mineral density and risk of breast cancer in older women. The Study of Osteoporotic Fractures. Study of Osteoporotic Fractures Research Group. Journal of the American Medical Association 276 1404-1408.
13. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW et al. 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Resources and Treatment 65 125-134.
14. Clemons M & Goss P 2001 Estrogen and the risk of breast cancer. New England Journal of Medicine 344 276-285.
15. Clemons M, Loijens L & Goss P 2000 Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treatment Reviews 26 291-302.
16. Collaborative Group on Hormonal Factors in Breast Cancer 1996a Breast cancer and hormonal contraceptives: collaborative study of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347 1713-1727.
17. Collaborative Group on Hormonal Factors in Breast Cancer 1996b Breast cancer and hormonal contraceptives: further results. Contraception 54 (Suppl. 3) 1-106.
18. Collaborative Group on Hormonal Factors in Breast Cancer 1997 Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 10 8411 women without breast cancer. Lancet 350 1047-1059.
19. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M et al. 1999 The effect of raloxifene on the risk of breast cancer on postmenopausal women: results from the MORE randomized trial. Journal of the American Medical Association 281 2189-2197.
20. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M & Krueger KA 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifene. Journal of the American Medical Association 287 216-220.
21. Cuzick J 2001 A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials. Annals of New York Academy of Sciences 949 122-133.
22. Dirx MJ, Voorrips LE, Goldbohm RA & Van Der Brandt PA 2001 Baseline recreational physical activity, history of sports participation, and postmenopausal breast carcinoma risk in the Netherlands Cohort Study. Cancer 92 1638-1649.
23. Dupont WD & Page DL 1985 Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine 312 146-151.
24. Easton DF, Bishop DT, Ford D & Crockford GP 1993 Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. American Journal of Human Genetics 52 678-701.
25. Egan KM, Stampfer MJ, Hunter D, Hankinson S, Rosner BA, Holmes M, Willet WC & Colditz GA 2002 Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. Epidemiology 13 138-145.
26. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association 282 637-645.
27. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 1371-1388.
28. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST & Eng CM 1998 Frequency and carrier risk associated with common BRCA 1 and BRCA 2 mutations in Ashkenazi Jewish breast cancer patients. American Journal of Human Genetics 63 45-51.
29. Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M & Goldstein L 1999 Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. Journal of Clinical Oncology 17 1680-1688.
30. Friedenreich CM 2001 Review of anthropometric factors and breast cancer risk. European Journal of Cancer Prevention 10 15-32.
31. Friedenreich CM, Courneya KS & Bryant HE 2001 Influence of physical activity in different age and life periods on the risk of breast cancer. Epidemiology 12 604-612.
32. Gambrell RD Jr 1996 Hormone replacement therapy and breast cancer risk. Archives of Family Medicine 5 341-348.
33. Gapstur SM, Morrow M & Sellers TA 1999 Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Heatlth Study. Journal of the American Medical Association 281 2091-2097.
34. Ginsburg ES 1999 Estrogen, alcohol, and breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology 69 299-306.
35. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS & Sellers TA 2000 Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. Journal of the American Medical Association 284 1791-1798.
36. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH & Neugut AI 2000 Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2 positive women: a decision analysis. Cancer Journal from Scientific American 6 13-20.
37. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH & Speitzer FE 1997 Postmenopausal hormone therapy and mortality. New England Journal of Medicine 336 1769-1775.
38. Heimdal K, Skovlund E & Moller P 2002 Oral contraceptives and risk of familial breast cancer. Cancer Detection and Prevention 26 23-27.
39. Henderson BE, Paganini-Hill A & Ross RK 1991 Decreased mortality in users of estrogen replacement therapy. Archives of Internal Medicine 151 75-78.
40. Hildreth NG, Shore RE & Dvoretsky PM 1989 The risk of breast cancer after irradiation of the thymus in infancy. New England Journal of Medicine 321 1281-1284.
41. Horn-Ross PL, John EM, Lee M, Stewart SL, Koo J, Sakoda LC, Shiau AC, Goldstein J, Davis P & Perez-Stable EJ 2001 Phytoestrogen consumption and breast cancer risk in a multiethnic population: the Bay Area Breast Cancer Study. American Journal of Epidemiology 154 434-441.
42. Horn-Ross PL, Hoggatt KJ, West DW, Krone MR, Stewart SL, Anton H, Bernstei CL, Deapen D, Peel D, Pinder R et al. 2002 Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 13 407-415.
43. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE & Willett WC 1997 Dual effects of weight and weight gain on breast cancer risk. Journal of the American Medical Association 278 1407-1411.
44. Hulka BS & Moorman PG 2001 Breast cancer: hormones and other risk factors. Maturitas 38 103-116.
45. Hunt K, Vessey M & McPherson K 1990 Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. British Journal of Obstetrics and Gynaecology 97 1080-1086.
46. Jernstrom H, Frenander J, Ferno M & Olsson H 1999 Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. British Journal of Cancer 80 1453-1458.
47. Johnson KC, Hu J & Mao Y 2000 Passive and active smoking and breast cancer risk in Canada, 1994-1997. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes and Control 11 211-221.
48. Khuder SA & Simon VJ Jr 2000 Is there an association between passive smoking and breast cancer? European Journal of Epidemiology 16 1117-1121.
49. Klijn JGM, Janin N, Cortes-Funes H & Colomer R 1997 Should prophylactic surgery be used in women at high risk of breast cancer? European Journal of Cancer 33 2149-2159.
50. Lacey JV Jr, Devesa SS & Brinton LA 2002 Recent trends in breast cancer and mortality. Environmental and Molecular Mutagenesis 39 82-88.
51. Lash TL & Aschengrau A 1999 Active and passive cigarette smoking and the occurence of breast cancer. American Journal of Epidemiology 149 5-12.
52. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J & Day NE 1992 Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes and Control 3 313-322.
53. Lee IM, Rexrode KM, Cook NR, Hennekens CH & Burin JE 2001 Physical activity and breast cancer risk: the Women's Health Study (United States). Cancer Causes and Control 12 137-145.
54. Lee MM & Lin SS 2000 Dietary fat and breast cancer. Annual Review of Nutrition 20 221-248.
55. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J et al. 1996 BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. Journal of the American Medical Association 275 1885-1892.
56. Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch SF, Surdam J, Orinion E, Slominski-Caster S, Watson P et al. 1997 A descriptive study of BRCAl testing and reactions to disclosure of test results. Cancer 79 2219-2228.
57. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO & Persson I 1999 Breast cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. International Journal of Cancer 88 339-344.
58. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL et al. 2002 Oral contraceptives and the risk of breast cancer. New England Journal of Medicine 346 2025-2032.
59. Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD & Qaqish B 2000 The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). Cancer Causes and Control 11 271-278.
60. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF et al. 2001 Breast cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. International Journal of Cancer 88 339-344.
61. Mezzetti M, La Vecchia C, De Carli A, Boyle P, Talamini R & Franceschini S 1998 Population attributable risk for breast cancer: diet, nutrition, and physical exercise. Journal of the National Cancer Institute 90 389-394.
62. Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, Risch HA & Preston DL 1989 Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. New England Journal of Medicine 321 1285-1289.
63. Narod SA 2001 Hormonal prevention of hereditary breast cancer. Annals of the New York Academy of Sciences 952 36-43.
64. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P et al. 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 356 1876-1881.
65. Newcomb PA, Trentham-Dietz DA, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Willet WC & Stampfer MJ 2001 Fracture history and risk of breast cancer and endometrial cancer. American Journal of Epidemiology 153 1071-1078.
66. Persson I, Adami HO, McLaughlin JK, Naessen T & Fraumeni JF Jr 1994 Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes and Control 5 523-528.
67. Powles T, Eeles R, Asheley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J & Davey J 1998 Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 98-101.
68. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX & Edwards BK 1999 SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute.
69. Ross RK, Paganini-Hill A, Wan PC & Pike MC 2000 Effect of hormone replacement therapy on breast cancer risk: estrogens versus estrogen plus progestin. Journal of the National Cancer Institute 92 328-332.
70. Sala E, Warren R, Mc Cann J, Duffy S, Luben R & Day N 2000 High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. International Journal of Epidemiology 29 629-636.
71. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA & Hoover RN 1999 Estrogen replacement therapy and breast cancer survival in a large screening study. Journal of the National Cancer Institute 91 264-270.
72. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L & Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association 283 485-491.
73. Schuurman AG, van den Brandt PA & Goldbohm RA 1995 Exogenous hormone use and risk of postmenopausal breast cancer: results from the Netherlands Cohort Study. Cancer Causes and Control 6 416-424.
74. Sellera TA, Mink PJ, Cerhan JR, Zheng W, Anderson K, Kushi LH & Folsom AR 1997 The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Annals of Internal Medicine 127 973-980.
75. Singletary KW & Gapstur SM 2001 Alcohol and breast cancer. Review of epidemiologic and experimental evidence and potential mechanism. Journal of the American Medical Association 286 2143-2151.
76. Smith-Warner S, Spiegelman D, Yaun SS, Van Den Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR et al. 1998 Alcohol and breast cancer in women: a pooled analysis of cohort studies. Journal of the American Medical Association 279 535-540.
77. Smith-Warner SA, Spiegelman D, Adami HO, Beeson WL, Van Den Brandt PA, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Graham S et al. 2001 Types of dietary fat and breast cancer: a pooled analysis of cohort studies. International Journal of Cancer 92 767-774.
78. Stallard S, Lilherland JC, Cordiner C, Dobson HM, George WD, Mallon EA & Hole D 2000 Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. British Medical Journal 320 348-349.
79. Stefanek ME, Helzlsouer KJ, Wilcox PM & Houn F 1995 Predictors of and satisfaction with bilateral prophylactic mastectomy. Preventive Medicine 24 412-419.
80. Struewing JP, Tarone RE, Brody LC, Li FP & Boice JD Jr 1996 BRCAI mutations in young women with breast cancer. Lancet 347 1493.
81. The Endogenous Hormones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616.
82. The Women's Health Initiative Study Group 1998 Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials 19 61-109.
83. Thompson WD 1994 Genetic epidemiology of breast cancer. Cancer 74 (Suppl 1) 279-287.
84. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M & Akiba S 1994 Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiotherapy Resources 138 209-223.
85. Torres-Sanchez L, Lopez Carrillo L, Lopez-Cervantez M, Rueda-Neria C & Wolff MS 2000 Food sources of phytoestrogens and breast cancer risk in Mexican women. Nutrition and Cancer 37 134-139.
86. Trentham-Dietz A, Newcomb PA, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Stampfer M & Willet WC 2000 Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11 533-542.
87. Trock B, Butler W, Clarke R & Hilakivi-Clarke L 2000 Meta-analysis of soy intake and breast cancer risk. Journal of Nutrition 130 690-691.
88. Tseng M, Weinberg CR, Umbach DM & Longnecker MP 1999 Calculation of population attributable risk for alcohol and breast cancer (United States). Cancer Causes and Control 10 119-123.
89. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A & Bernstein A 1997 Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Resources 57 678-3681.
90. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L et al. 2000 Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. American Journal of Epidemiology 152 514-527.
91. Van Hoften C, Burger H, Peeters PH, Grobbe DE, Van Noord PA & Leufkens HG 2000 Long-term oral contraceptives use increases breast cancer risk in women over 55 years of age: the DOM Cohort. International Journal of Cancer 87 591-594.
92. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N & Boyle P 1998 Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352 93-97.
93. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG et al. 1999 Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. Journal of the National Cancer Institute 91 1847-1856.
94. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N & Boyle P 2002 Tamoxifen for breast cancer among hysterectomised women. Lancet 359 1122-1124.
95. Vogel VG 2001 Reducing the risk of breast cancer with tamoxifen in women at increased risk. Journal of Clinical Oncology 19 (Suppl 18) 87-92.
96. Wartenberg D, Calle E, Thun MJ, Heath CW Jr, Lally C & Woodruff T 2000 Passive smoking exposure and female breast cancer mortality. Journal of the National Cancer Institute 92 1666-1673.
97. Willis DB, Calle EE, Miracle-McMahill HL & Heath CW Jr 1996 Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7 449-457.
98. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Journal of the American Medical Association 288 321-333.
99. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AM, West DW, Kolonel LN, Rosenthal JF, Hoover RN & Pike MC 1996 Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiology Biomarkers and Prevention 5 901-906.
100. Wu AH, Pike MC & Stram DO 1999 Meta-analysis: dietary fat intake, serum estrogen levels, and risk of breast cancer. Journal of the National Cancer Institute 91 529-534.
101. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D & Felson DT 1997 Bone mass and the risk of breast cancer among postmenopausal women. New England Journal of Medicine 336 611-617.